BioMarin Reports Q3 2026 Revenues of $1.025 Billion, Updates Full-Year Guidance
BioMarin Pharmaceutical reported third-quarter 2026 total revenues of $1.025 billion, a 32% increase year-over-year, driven by contributions from acquired products including GALAFOLD and POMBILITI plus OPFOLDA. However, the company reported a GAAP net loss of $123 million due to acquisition-related expenses and IPR&D charges, and lowered its full-year 2026 Non-GAAP Diluted EPS guidance to a range of $2.80 to $3.10.
Key points
- Third-quarter 2026 total revenues rose 32% year-over-year to $1.025 billion.
- GAAP net loss widened to $123 million for the third quarter ended September 30, 2026, compared to a net loss of $31 million a year earlier.
- Full-year 2026 Non-GAAP Diluted EPS guidance was revised to between $2.80 and $3.10, down from prior expectations.
- The FDA set a PDUFA target action date of May 30, 2027, for VOXZOGO in hypochondroplasia.
The filing
Written by AI (Google Gemini, gemini-3.5-flash-lite) on Nov 3, 2026, 8:16 AM ET, from the text of the filing and its press-release exhibits only.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.